Adverse-event reporting in clinical trials largely follows the Common Terminology Criteria for Adverse Events (CTCAE), with CTCAE Version 4.03 the most up-to-date (published May 28, 2009 on CTCAE v4.0 and reviewed June 14, 2010 on CTCAE v4.03).
In the literature on EGFRI skin toxicity, however, it is acknowledged that CTCAE grading is not EGFRI-specific, which is the reason for criticism regarding its clinical utility.1,2,3 Since current treatment recommendations are increasingly following a graduation that differentiates between mild, moderate and severe skin reactions,1,4 recommendations for the management of EGFRI-associated skin changes on this website adhere to this simplified clinical grading rather than the more complex CTCAE grading system.
For medical documentation purpose and common language use, we have also added information on the relevant ICD10 codes, as published on WHO ICD10.
1Lynch TJ, Jr. et al. Oncologist 2007; 12: 610-621.
2Segaert S & Van Cutsem E. Ann Oncol 2005; 16: 1425-1433.
3Tan EH & Chan A. Ann Pharmacother 2009; 43: 1658-1666.
4Segaert S. Targeted Oncol 2008; 3: 245-251.